WO2015017313A3 - Assays and methods for assessing immunogenic cell death, efficacy of anti-cancer therapy, and identifying potentially efficacious therapies - Google Patents

Assays and methods for assessing immunogenic cell death, efficacy of anti-cancer therapy, and identifying potentially efficacious therapies Download PDF

Info

Publication number
WO2015017313A3
WO2015017313A3 PCT/US2014/048385 US2014048385W WO2015017313A3 WO 2015017313 A3 WO2015017313 A3 WO 2015017313A3 US 2014048385 W US2014048385 W US 2014048385W WO 2015017313 A3 WO2015017313 A3 WO 2015017313A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer therapy
assessing
identifying
efficacy
cell death
Prior art date
Application number
PCT/US2014/048385
Other languages
French (fr)
Other versions
WO2015017313A2 (en
Inventor
Silvia FORMENT
Encouse B. GOLDEN
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of WO2015017313A2 publication Critical patent/WO2015017313A2/en
Publication of WO2015017313A3 publication Critical patent/WO2015017313A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods, compositions and kits for identifying, assessing or quantifying immunogenic cell death, for assessing or determining the efficacy of an anti-cancer therapy, for identifying a potentially efficacious anti-cancer therapy, for identifying, assessing or quantifying the effect of an antic-cancer agent on a normal or non-cancerous cell, and for identifying a subject who may benefit from an anti-cancer therapy by detecting or measuring or quantifying one, two or three of the following: (a) cell surface translocation of calreticulin (CRT), (b) extracellular release of HMGB1, and (c) extracellular release of adenosine-5'- triphosphate (ATP). An increase in one, two or three of the above where the increase is at least about 25%, 50%), 75%, 100%), 150%), two times, three times, four times, five times or more greater than a baseline, a control or a measure made or value obtained prior to exposure to one or more anti-cancer agents may be diagnostic.
PCT/US2014/048385 2013-07-29 2014-07-28 Assays and methods for assessing immunogenic cell death, efficacy of anti-cancer therapy, and identifying potentially efficacious therapies WO2015017313A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361859351P 2013-07-29 2013-07-29
US61/859,351 2013-07-29

Publications (2)

Publication Number Publication Date
WO2015017313A2 WO2015017313A2 (en) 2015-02-05
WO2015017313A3 true WO2015017313A3 (en) 2015-11-05

Family

ID=52432545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/048385 WO2015017313A2 (en) 2013-07-29 2014-07-28 Assays and methods for assessing immunogenic cell death, efficacy of anti-cancer therapy, and identifying potentially efficacious therapies

Country Status (1)

Country Link
WO (1) WO2015017313A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US20240003893A1 (en) * 2020-11-30 2024-01-04 Cz Biohub Sf, Llc Reconstitution of a split-halotag via orthogonal tag-binding domains
CN113063948A (en) * 2021-03-09 2021-07-02 南通大学 Application of HMGB1 in evaluating non-small cell lung cancer condition and clinical efficacy
WO2024025962A1 (en) * 2022-07-27 2024-02-01 William Marsh Rice University Techniques for magnetic nanocluster-based combination therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070161001A1 (en) * 2004-03-04 2007-07-12 Dena Leshkowitz Quantifying and profiling antibody and t cell receptor gene expression
US20070178532A1 (en) * 2003-03-24 2007-08-02 The Gov.Of The Us As Represented By The Secretary Identification, quantification, and characterization of t cells and t cell antigens
US20120302462A1 (en) * 2009-11-09 2012-11-29 Bjorn Onfelt System and Method for Detecting and Quantifying Active T-cells or Natural Killer Cells
US20130052160A1 (en) * 2010-04-22 2013-02-28 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178532A1 (en) * 2003-03-24 2007-08-02 The Gov.Of The Us As Represented By The Secretary Identification, quantification, and characterization of t cells and t cell antigens
US20070161001A1 (en) * 2004-03-04 2007-07-12 Dena Leshkowitz Quantifying and profiling antibody and t cell receptor gene expression
US20120302462A1 (en) * 2009-11-09 2012-11-29 Bjorn Onfelt System and Method for Detecting and Quantifying Active T-cells or Natural Killer Cells
US20130052160A1 (en) * 2010-04-22 2013-02-28 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MENGER ET AL.: "Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death", SCIENCE TRANSLATIONAL MEDICINE, vol. 4, no. 143, 18 July 2012 (2012-07-18), pages 1 - 9, XP055234012, ISSN: 1946-6234 *

Also Published As

Publication number Publication date
WO2015017313A2 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
Kaur et al. Mitochondrially targeted redox probe reveals the variations in oxidative capacity of the haematopoietic cells
WO2015017313A3 (en) Assays and methods for assessing immunogenic cell death, efficacy of anti-cancer therapy, and identifying potentially efficacious therapies
BR112015015287A2 (en) ph formulation and indicating device
BR112018002428A2 (en) “Antibodies, polynucleotide, vector, cell, method of expressing the antibody, kit, method for detecting the presence or level of human or monkey pd-l1 in a sample, method of identifying an individual with a disorder, method for monitoring therapeutic response, pharmaceutical composition, method for treating a condition in a subject and use of the antibody
BR112015023783A2 (en) Method for diagnosis and treatment of cancer metastasis
AR095363A1 (en) BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1
BR112014018331A8 (en) BIOMARKERS AND COMBINED THERAPIES USING ONCOLYTIC VIRUSES AND IMMUNOMODULATION
BR112016004305A2 (en) diagnostic methods and compositions for treating glioblastoma
BR112017004773A2 (en) biomarkers to evaluate breast cancer
BR112014007214A2 (en) prediction of cardiovascular risk event and its use
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112014026582A2 (en) method for identifying agents capable of inducing respiratory and matrix sensitization and analytical kits for use in the method
BR112013006683A2 (en) breast cancer diagnosis
BR112017023726A2 (en) detection of microbial virulence factors in the oral cavity
BR112014029268A2 (en) measuring apparatus for determining a measured value in a gas stream, and method for determining a measured gas content in a gas stream
BR112018073178A2 (en) method, matrix and use thereof
MX2017003370A (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm.
BR112013013457A2 (en) methods for identifying a patient or subject, for predicting a subject's sensitivity, for identifying subjects who have parkinson's disease, and for determining the subject's response to therapy and assay for selecting compounds and compositions
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
BR112016008956A2 (en) DETECTION OF ENZYME CLEAVAGE ACTIVITY
BR112012022014A2 (en) probe indicating boundary boundaries between materials
JP2018004657A5 (en)
BR112017011026A2 (en) analytical methods and arrangements for use therein
Wolfe Fibromyalgia research criteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14832468

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14832468

Country of ref document: EP

Kind code of ref document: A2